SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001140361-23-016775 from BED BATH & BEYOND INC (CIK 0000886158)

BED BATH & BEYOND INC (CIK 0000886158)
Date: April 5, 2023 · CIK: 0000886158 · Accession: 0001140361-23-016775

AI Filing Summary & Sentiment

File numbers found in text: 000-20214

Date
April 5, 2023
Author
/s/ Sue Gove
Form
CORRESP
Company
BED BATH & BEYOND INC (CIK 0000886158)

Letter

VIA EDGAR Division of Corporation Finance Office of Trade & Services Attention: Bed Bath & Beyond Inc. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Filed March 31, 2023 File No. 000-20214

Dear Mr. Fetterolf and Ms. Ransom,

Bed Bath & Beyond Inc. (the “Company”) sets forth below our response to the letter, dated April 4, 2023 (the “Letter”), containing the comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the above referenced Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A, filed with the Commission on March 31, 2023.

In order to facilitate your review, we have restated the Staff’s comments in this letter, and we have set forth the Company’s responses immediately below the Staff’s comments.

Concurrent with the submission of this letter, the Company has filed a Definitive Proxy Statement on Schedule DEF 14A (the “Definitive Proxy Statement”) incorporating the Company’s response to the Staff’s Letter. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Definitive Proxy Statement.

Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A filed March 31, 2023

Proposal 1: The Reverse Split Proposal

Certain Risks Associated with the Reverse Stock Split, page 12

1.

Staff’s comment: Revise to discuss the risks you acknowledge in the prospectus dated March 30, 2023, including the issuer's need for liquidity, dilution with the issuance of additional shares of Common Stock, volatility in trading and market prices of the Common Stock, to name just a few risks as examples that should be discussed.

Response: The Company acknowledges the Staff’s comment and has supplemented the disclosure provided on pages 12 to 13 of the Definitive Proxy Statement.

Securities and Exchange Commission

April 5, 2023

Page 2

The Reverse Stock Split may not increase the price of Common Stock, page 12

2.

Staff’s comment: We note your disclosure that "[o]ther factors, such as our financial results, market conditions and the market perception of our business, may adversely affect the stock price . . . ." Revise to discuss how issuances pursuant to the Sales Agreement and Purchase Agreement may adversely affect the stock price. In connection therewith, here or as a new risk, discuss how the market price of your Common Stock may impact the proceeds raised pursuant to such agreements, and how a declining price may thereby increase the likelihood of an "Equity Termination Event" under the Credit Agreement and thereby trigger an "Event of Default" that could lead to bankruptcy.

Response: The Company acknowledges the Staff’s comment and has supplemented the disclosure provided on pages 13 to 14 of the Definitive Proxy Statement.

* * *

We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions related to this letter, please direct any such requests or questions to Christian O. Nagler of Kirkland & Ellis LLP at (212) 446-4660 or cnagler@kirkland.com.

Sincerely,
/s/ Sue Gove

Show Raw Text
CORRESP
1
filename1.htm

      650 LIBERTY AVENUE, UNION, NJ 07083

      April 5, 2023

      VIA EDGAR

      U.S. Securities and Exchange Commission

      Division of Corporation Finance

      Office of Trade & Services

      100 F Street, NE

      Washington, DC 20549

                Attention:

                Brian Fetterolf

                Mara Ransom

                Re:

                Bed Bath & Beyond Inc.

                Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A

                Filed March 31, 2023

                File No. 000-20214

          Dear Mr. Fetterolf and Ms. Ransom,

          Bed Bath & Beyond Inc. (the “Company”) sets forth below our response to the letter, dated April 4, 2023 (the “Letter”), containing
            the comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the
            above referenced Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A, filed with the Commission on March 31, 2023.

          In order to facilitate your review, we have restated the Staff’s comments in this letter, and we have set forth the Company’s responses immediately below the Staff’s comments.

          Concurrent with the submission of this letter, the Company has filed a Definitive Proxy Statement on Schedule DEF 14A (the “Definitive Proxy Statement”) incorporating the
            Company’s response to the Staff’s Letter. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Definitive Proxy Statement.

          Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A filed March 31, 2023

          Proposal 1: The Reverse Split Proposal

          Certain Risks Associated with the Reverse Stock Split, page 12

                    1.

                    Staff’s comment: Revise to discuss the risks you acknowledge in the
                        prospectus dated March 30, 2023, including the issuer's need for liquidity, dilution with the issuance of additional shares of Common Stock, volatility in trading and market prices of the Common Stock, to name just a few risks as
                        examples that should be discussed.

          Response: The Company acknowledges the Staff’s comment and has supplemented the
              disclosure provided on pages 12 to 13 of the Definitive Proxy Statement.

                      Securities and Exchange Commission

                      April 5, 2023

                      Page 2

          The Reverse Stock Split may not increase the price of Common Stock, page 12

                    2.

                    Staff’s comment: We note your disclosure that "[o]ther factors, such as our
                        financial results, market conditions and the market perception of our business, may adversely affect the stock price . . . ." Revise to discuss how issuances pursuant to the Sales Agreement and Purchase Agreement may adversely
                        affect the stock price. In connection therewith, here or as a new risk, discuss how the market price of your Common Stock may impact the proceeds raised pursuant to such agreements, and how a declining price may thereby increase the
                        likelihood of an "Equity Termination Event" under the Credit Agreement and thereby trigger an "Event of Default" that could lead to bankruptcy.

          Response: The Company acknowledges the Staff’s comment and has supplemented the
              disclosure provided on pages 13 to 14 of the Definitive Proxy Statement.

          * * *

          We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions related to this letter, please direct any such requests or questions to Christian O. Nagler of Kirkland & Ellis
            LLP at (212) 446-4660 or cnagler@kirkland.com.

                      Sincerely,

                    /s/ Sue Gove

                      Sue Gove

                    President & Chief Executive Officer

                      Bed Bath & Beyond Inc.

          VIA EMAIL

          cc:          David Kastin, Executive Vice President, Chief Legal Officer & Corporate Secretary

          Bed Bath & Beyond Inc.

          Christian O. Nagler, P.C.

          Tamar Donikyan

          Christina Thomas

          Kirkland & Ellis LLP